Johnson & Johnson's (NYSE:JNJ) Janssen Biotech is now obligated to make a $50 million milestone payment to Pharmacyclics, Inc. (NASDAQ:PCYC), which international Phase III randomized, multicenter, open-label clinical trial, RESONATE, or PCYC-1112, ...
Related articles »